Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 4/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 14/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24098992 | 0.86 | APOL1 (0.55) | APOL1PPARGCXCR2TACR1CYP2C9 | |
| SCHEMBL24099131 | 0.85 | APOL1 (0.60) | APOL1PPARGCXCR2TACR1CYP2C9 | |
| SCHEMBL24098987 | 0.85 | APOL1 (0.60) | APOL1PPARGCXCR2TACR1 | |
| SCHEMBL24907011 | 0.84 | APOL1 (0.59) | APOL1PPARGCXCR2TACR1 | |
| SCHEMBL24098917 | 0.84 | APOL1 (0.59) | APOL1PPARGCXCR2TACR1CYP2C9 | |
| SCHEMBL24099177 | 0.84 | APOL1 (0.63) | APOL1PPARGCXCR2TACR1CYP2C9 | |
| SCHEMBL24099292 | 0.83 | APOL1 (0.58) | APOL1PPARGCXCR2CYP2C9 | |
| SCHEMBL24098998 | 0.83 | APOL1 (0.57) | APOL1PPARGCXCR2TACR1CYP2C9 | |
| SCHEMBL30325247 | 0.81 | APOL1 (0.55) | APOL1PPARGCXCR2CYP2C9 | |
| SCHEMBL24098678 | 0.81 | PPARG (0.66) | APOL1PPARGCXCR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | APOL1 1/4885PPARG 2747/4885CXCR2 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.